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Catheter Obstruction of Intrathecal Drug Administration System
-A Case Report- 
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Intrathecal drug administration system (ITDAS) can reduce the side effects while increasing the effectiveness 
of opioids compared to systemic opioid administration. Therefore, the use of ITDAS has increased in the 
management of cancer pain and chronic intractable pain. Catheter obstruction is a serious complication of 
ITDAS. Here, we present a case of catheter obstruction by a mass formed at the side hole and in the lumen. 
A 37-year-old man suffering from failed back surgery syndrome received an ITDAS implantation, and the ITDAS 
was refilled with morphine every 3 months. When the patient visited the hospital 18 months after ITDAS 
implantation for a refill, the amount of delivered morphine sulfate was much less than expected. Movement 
of the pump rotor was examined with fluoroscopy; however, it was normal. CSF aspiration through the catheter 
access port was impossible. When the intrathecal catheter was removed, we observed that the side hole and 
lumen of the catheter was plugged. (Korean  J  Pain  2012;  25:  47-51)
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Intrathecal injection of opioids has the same pain control 
effect with 1/300 quantity of oral administration; there-
fore, it can reduce complications arising from the use of 
opioids  [1].  The  intrathecal  drug  administration  system 
(ITDAS) is an instrument that can continually inject a pro-
grammed amount of opioids for a long period of time and 
was first used for pain management in cancer patients in 
1981 [2]. In 1982, the Infusaid pump
Ⓡ was the first com-
mercialized implantable infusion pump (Shiley Infusaid Inc., 
N o r w o o d ,  M A ,  U S A )  [ 3 ] ,  a n d  i n  1 9 9 1 ,  t h e  S y n c h r o M e d
Ⓡ 
pump (Medtronic Inc., Minneapolis, MN, USA), which is pro-
grammable, received FDA approval in the United States [4].
Recently, the procedure has been performed in pa-
tients with non-cancer pain that cannot be controlled by 
other  treatment  such  as  failed  back  surgery  syndrome, 
complex  regional  pain  syndrome,  postherpetic  neuralgia, 
and peripheral neuropathy [5]. This non-cancer pain lasts 
for longer periods compared to the pain from cancerous 
diseases; thus, the follow-up observation period after in-
serting the ITDAS becomes longer with a higher risk of 
more complications. 
Regarding the complications of ITDAS, catheter ob-48 Korean J Pain Vol. 25, No. 1, 2012
Fig. 1. Movement of the 
Rotor examined by a fluoro-
scope (arrow). Before (A) 
and after (B) the priming 
bolus injection. The rotor was
functioning normally.
struction is a very serious complication, and there are clinical 
recommendations  on  the  concentration  and  quantity  of 
opioids to prevent its occurrence [6]. Despite following the 
recommendations  that  prevent  catheter  tip  mass  for-
mation, the authors experienced a case where the catheter 
was obstructed and drug administration was stopped be-
cause of a mass in the side hole and lumen and hence, 
are reporting this case with a literature review.
CASE  REPORT
A 37-year-old male patient 163 cm tall weighing 45.6 
kg visited the hospital with paraplegia, voiding difficulty, 
hypesthesia  below  L1,  and  pain  with  a  visual  analogue 
scale (VAS) score 8/10 as post lumbar surgery syndrome, 
w h i c h  o c c u r r e d  a f t e r  r e c e i v i n g  s u r g e r y  f o r  c o n g e n i t a l  
scoliosis. Twenty-four months prior to his visit, he had re-
ceived treatment from an another hospital, which included 
caudal epidural block and epidural adhesiolysis, and medi-
cation  including  transdermal  fentanyl  patch  (Durogesic 
D-trans
Ⓡ, Janssen Korea Ltd., Seoul, Korea) 37 mcg/h, 
oxycodone  hydrochloride  (Oxycontin  CR
Ⓡ,  Mundipharma 
K o r e a  L t d . ,  S e o u l ,  K o r e a )  4 0  m g / d ,  U l t r a c e t
Ⓡ  (Janssen 
Korea  Ltd.,  Seoul,  Korea)  4  tablets/d,  and  pregabalin 
(Lyrica
Ⓡ, Pfizer Korea Inc., Seoul, Korea) 600 mg/d was 
p r e s c r i b e d ;  h o w e v e r ,  t h e r e  w a s  n o  i m p r o v e m e n t  i n  h i s  
pain. Hence, 20 months before visiting our hospital, the 
patient  had  an  ITDAS  (SynchroMed
Ⓡ I I ,  M e d t r o n i c  I n c . , 
Minneapolis, MN, USA) inserted with the catheter tip posi-
tioned  at  the  L1  body  height.  After  the  procedure,  the 
ITDAS was refilled with 18 ml of morphine sulfate (Highmol
Ⓡ 
1 0  m g / m l ,  B C W o r l d  P h a r m .  C o . ,  K o r e a )  e v e r y  t h r e e  
months, and the injected quantity was maintained between 
0.95-1.7 mg/d, and the pain was controlled with a V AS 
score of 3-4/10. 
Fifteen months after inserting the ITDAS, the remain-
ing medication was removed to refill the device; however, 
17 ml of morphine sulf ate was left in the de vice, w hich 
should have been 5.6 ml had the injections been normal. 
Other than increased pain with a VAS score of 8/10, there 
w e r e  n o  n e u r o l o g i c a l  a b n o r m a l i t i e s  t h a t  h a d  n e w l y  o c-
curred, and the test program within the instrument was 
functioning normally without any failures. The patient had 
undergone surgery in the left elbow joint two months prior; 
thus, a temporary software problem due to the monopolar 
electrocautery during the surgery was believed to be the 
cause of the problem. After disposing the remaining medi-
cation, another 18 ml of morphine sulfate was refilled, and 
the program was reset. At that time, the patient’s pain 
had  not  controlled;  therefore,  oxycodone  hydrochloride 
(IRcodon
Ⓡ,  Mundipharma  Korea  Ltd.,  Seoul,  Korea)  30 
mg/d was taken by the patient whenever there was pain. 
A  transdermal  fentanyl  patch  (Durogesic  D-trans
Ⓡ, 
Janssen Korea Ltd., Seoul, Korea) 25 mcg/h was addition-
ally prescribed.
Three months later, when the patient visited the hos-
pital to refill the device, the 18 ml of morphine sulfate were 
still in the device, and the test program in the instrument 
was functioning normally. To examine whether the instru-
ment was operating properly, priming bolus mode was ini-
tiated, and 15 minutes later, the movement of the rotor 
was confirmed under the fluoroscope, which confirmed it 
was operating normally (Fig. 1). Therefore, it seemed that 
there could be a catheter obstruction rather than problems SM Rhee, et al / Catheter Obstruction of ITDAS 49
Fig. 2. (A) Removal of the 
catheter from the patient. 
The side hole of the catheter
was plugged. (B) Magnified 
picture of the catheter tip.
with the instrument itself; therefore, it was decided to as-
pirate some of the cerebrospinal fluid from the catheter’s 
access port. The total volume of the catheter was calcu-
lated as 0.132 ml; thus, a 1 ml needle was used. The needle 
was inserted into the access port and aspiration was at-
tempted, but the authors were unable to aspirate any of 
the cerebrospinal fluid. An emergency kit was prepared 
and 0.05 ml of normal saline was injected into the cathe-
ter’s access port; however, it was unable to enter the port. 
Another attempt was made with 0.05 ml, but there was 
strong pressure and the normal saline did not go in at all. 
Catheter kinking or blockage by a mass was suspected; 
therefore, the decision was made to extract the catheter 
for confirmation. The catheter and instrument were ex-
tracted, and it was confirmed that the catheter’s side hole 
was blocked by a tissue mass, and it was also observed 
that the catheter’s lumen was blocked (Fig. 2). We had 
planned to exchange the catheter, but the patient and his 
wife were worried about repeated occurrences of the cath-
e t e r  b e i n g  b l o c k e d .  T h e y  w a n t e d  t o  r e m o v e  t h e  I T D A S ; 
therefore, the ITDAS was completely removed. At present, 
the pain is maintained at a VAS score of 6/10 with a trans-
d e r m a l  f e n t a n y l  p a t c h  ( D u r o g e s i c  D - t r a n s
Ⓡ,  Janssen 
Korea Ltd., Seoul, Korea) 50 mcg/h, pregabalin (Lyrica
Ⓡ, 
Pfizer Kor ea In c., Seo ul, Kor ea) 600 mg/d, t r amad o l 
hydrochloride 100 mg/d (Tramaconti
Ⓡ, Whanin Pharm co., 
Seoul, Korea), and oxycodone hydrochloride (Oxycontin CR
Ⓡ, 
Mundipharma Korea Ltd., Seoul, Korea) 40 mg/d.
DISCUSSION
A n i n t r a t h ec a l  m a s s t h a t  o c c u r r ed  in  t h e  t ip  o f a n 
ITDAS catheter was first reported in a patient with chronic 
intractable pain in 1991 [7]. The formation of granulomas 
i n  i n t r a t h e c a l  c a t h e t e r s  h a s  b e e n  r e p o r t e d  t o  h a v e  a  
0.04% occurrence rate two years after insertion of the 
catheter and 1.15% six years after insertion [8]. Granulomas 
are a result of responses to local inflammation due to the 
activation of endothelial cells, granulocytes, and mono-
cytes [9]. Granulomas are caused by active drugs, preser-
vatives, indolent organisms, changes in pH, the material 
of the catheter (silicon), and injury during insertion [10]. 
Masses that form at the catheter tip press on the spinal 
cord to cause neurological abnormalities, and when treat-
ment is delayed, it may cause permanent damage to the 
spinal cord [8]. 
S y m p t o m s  f r o m  g r a n u l o m a s  a r e  m o t o r  w e a k n e s s ,  
sensory  loss,  changes  in  reflex  functions,  and  bladder 
dysfunction. Other symptoms can be numbness, tingling, 
burning, hyperesthesia, hyperalgesia, and radicular pain at 
the same level as the catheter tip. A granuloma is sus-
pected when the required amount of opioids increases for 
the same amount of analgesia effect and pain control [11]. 
When neurological abnormalities progress rapidly, a gran-
uloma should be surgically removed as soon as possible for 
a better prognosis, and even though neurological abnor-
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in  treatment  can  make  recovery  difficult;  thus,  surgery 
should be performed promptly [7,12]. When the neurological 
disorder is not severe or when the pressure from the mass 
on the nerve is weak, it can be treated without surgical 
removal. If administration of the drug is stopped or the 
m e d i c a t i o n  i s  r e p l a c e d  w i t h  n o r m a l  s a l i n e ,  t h e  s i z e  o f  
granuloma  can become  smaller  within  2-5  months  [12]. 
Neurological examination should be performed before in-
s e r t i n g  t h e  I T D A S ,  a n d  r e g u l a r  e x a m i n a t i o n s  s h o u l d  b e 
performed after insertion to detect neurological abnormal-
ities early on so it can be treated with relatively simple 
methods such as stopping the administration of the medi-
cation rather than invasive methods such as surgery. In 
our case, no new neurological abnormalities occurred be-
sides increased pain. In addition, since an MRI could not 
be performed due to the economic situation of the patient 
in our case, and the test program within the instrument 
indicated normal functioning, we suspected catheter ob-
struction based on increased pain, reduced administration 
of morphine sulfate lower than the programmed amount, 
and the observation of normal movement of the rotor with 
fluoroscopy. Inserting a needle into the CAP for catheter 
patency check and performing dye injection after CSF as-
piration could be considered, but according to the experi-
ence of the authors, the inserted catheter’s length was 
60-80 cm long; thus, it would be very difficult to suction 
CSF thr ough the C AP. Additionally, as in our case, the 
movement of the rotor must be checked because due to 
the structure of the SynchroMed II
Ⓡ; the force that admin-
isters the medication is from pressurized gas, which pres-
surizes the bellows type drug reservoir to push the medi-
cation into the catheter, and the rotor only has the role 
of administering the exact amount of medication. In other 
words, the rotor is unrelated to the propulsion and simply 
a c t s  a s  t o  p r e c i s e l y  c o n t r o l  t h e  q u a n t i t y  o f  m e d i c a t i o n 
administered. 
Various methods to prevent the formation of masses 
in the ITDAS catheter tip have been introduced. First, since 
the concentration and dose of the medication is higher and 
the flow rate is lower, there is a high possibility of mass 
f o r m a t i o n ;  t h u s ,  i t  i s  r e c o m m e n d e d  t h a t  t h e  m a x i m u m 
concentration should be 20 mg/ml, and the maximum dose 
should not to exceed 15 mg/d [6]. Since the CSF space is 
wider, it lowers the possibility of a granuloma; therefore, 
it is best to position the catheter tip at T7-T10 or L1-L2 
where the CSF space is wide [6]. If the catheter tip is lo-
cated  lower  than  the  conus  medullaris,  it  can  minimize 
neurological abnormalities even when a mass is formed [11]. 
However, in lipophilic drugs such as baclofen, the catheter 
tip should be located near the targeted spinal nerve, but 
morphine is a hydrophilic drug so placing it lower than the 
conus medullaris can reduce complications. In our case, a 
mass still formed despite an inserted morphine concen-
tration of 10 mg/ml, used dose 107 mg/d, and the catheter 
tip being located at L1. Therefore additional methods such 
as regular flushing should be considered to prevent mass 
formation. Moreover, the catheter used in our case was 
a side-hole type; therefore, if end-hole types are used in 
the future, this may help to reduce mass formation.
In conclusion, to prevent complications from mass for-
mation in a catheter tip, a suitable location for the catheter 
should be selected at the time of ITDAS insertion, and the 
administered dose and concentration of morphine should 
be as low as possible. In addition, to detect a catheter ob-
struction early on, under-infusion must be checked at the 
time of medication refill. When rotor movement is normal, 
the possibility of a catheter obstruction must be considered.
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